Skip to main content

Table 1 Details of clinico-pathologic data and expression of Mcm2 in diffuse large B-cell lymphomas

From: Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis

Variable Categorisation n analysable %
Clinico-pathologic data:
Age at diagnosis
  median 67 years (interquartile range 54–75 years)
  <65 years 69 43.1
  ≥65 years 91 56.9
Gender
  male 97 53.3
  female 85 46.7
Ann Arbor stage
  1 27 17.3
  2 50 32.1
  3 34 21.8
  4 45 28.8
International prognostic index (IPI)
  0 2 1.3
  1 66 43.4
  2 29 19.1
  3 32 21.1
  4 23 15.1
Bone marrow involvement
  yes 44 28.6
  no 110 71.4
Extranodal involvement
  yes 54 35.8
  no 97 64.2
Bulky disease
  yes 94 64.4
  no 52 35.6
Chemotherapy
  no therapy 7 4.6
  CHOP 69 45.1
  other 77 50.3
Serum levels of LDH at diagnosis
  median 306 U/l (interquartile range 185–443 U/l)
  <300 U/l 61 49.2
  ≥300 U/l 63 50.8
Immunohistochemistry:
Mcm2 immunoreactivity
  median 38% (interquartile range 29%–48%)
  <40% 113 53.6
  ≥40% 98 46.4